Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection
Authors:
Preprint
- 24 April 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Purpose. Albuvirtide (ABT) is the first long-acting HIV fusion inhibitor originally developed in China, blocking the invasion of HIV-1 virus into target cells. This study aimed to compare the pharmacokinetics, tolerability, and safety of ABT following a single intravenous (IV) bolus injection or intravenous drip in healthy Chinese subjects.Methods. A single-center, randomized, open-label, single-period, parallel phase I clinical trial was conducted. 30 subjects were randomly divided into 3 groups in a ratio of 1:1:1. After an overnight fast, all subjects received a single dose administration of 320 mg ABT by intravenous drip for 45 min (Group A) or bolus injection for 0.5 min (Group B) or bolus injection for 3 min (Group C). ABT plasma concentrations were analyzed using validated enzyme-linked immunosorbent assay. Noncompartmental analysis was used to evaluate PK parameters.Results. The median value of time to reach maximum concentration was 0.75 h in group A and 0.16 h in both group B and C, elimination half-life, mean residence time, apparent clearance and apparent volume of distribution was similar among three groups. The 90% confidence intervals of geometric mean ratios of PK parameters for group B and C relative to group C are mainly within 85–120%. All AEs in this study were mild, according to the CTCAE guidelines and the study investigator’s judgement.Conclusion. ABT bolus injection for 0.5 min and 3 min are expected well tolerated and to have similar pharmacokinetic characteristics as IV drip for 45 min, thus offering potential clinical benefits.Keywords
All Related Versions
This publication has 16 references indexed in Scilit:
- Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation resultsXenobiotica, 2016
- Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion InhibitorPLOS ONE, 2012
- Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapyScandinavian Journal of Infectious Diseases, 2011
- An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and LongIn VivoHalf-LifeAntimicrobial Agents and Chemotherapy, 2010
- HIV entry inhibitors and their potential in HIV therapyMedicinal Research Reviews, 2008
- Pharmacokinetics, Pharmacodynamics and Drug Interaction Potential of EnfuvirtideClinical Pharmacokinetics, 2005
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South AmericaNew England Journal of Medicine, 2003
- HIV-1 Drug Resistance in Newly Infected IndividualsJAMA, 1999
- Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entryNature Medicine, 1998
- Drug Interactions in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 1996